Clinical trial
Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable…
NCT00003326 · Theradex, Industry · Unknown status
Key facts
| NCT number | NCT00003326 |
|---|---|
| Title | Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus |
| Official title | A Phase II Trial of Paclitaxel (TAXOL) Administered as a Weekly One Hour Infusion in Patients With Advanced Esophageal Cancer |
| Lead sponsor | Theradex, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Esophageal Cancer |
| Intervention type | Drug |
| Interventions | paclitaxel |
| Enrollment | 100 |
| Start date | Sep 1, 1997 |
| First posted | May 20, 2004 |
| Last update posted | Jul 24, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: